跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
欣安立适 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Recombinant Zoster Vaccine(CHO Cell)
Approved
生物制品
Recombinant Zoster Vaccine(CHO Cell)
GlaxoSmithKline Biologicals SA
🇨🇳 National Medical Products Administration
Approval Date
Mar 20, 2024
Approval ID
8YzVYkJzWts
Company
GlaxoSmithKline Biologicals SA
Type
生物制品
Approval Details
Approval Id
8YzVYkJzWts
Approval Number
国药准字SJ20190026
Generic Name
重组带状疱疹疫苗(CHO细胞)
Generic Name En
Recombinant Zoster Vaccine(CHO Cell)
Trade Name
欣安立适
Drug Type
生物制品
Dosage Form
注射剂
Strength
复溶后每1次人用剂量0.5ml,含gE蛋白50μg。
Reg Date
2024-03-20
Expired Date
2029-03-19
Company Name
GlaxoSmithKline Biologicals SA
Production Company Name
GlaxoSmithKline Biologicals SA
Company Detail Path
/organization/glaxosmithkline-biologicals-sa
Production Company Detail Path
/organization/glaxosmithkline-biologicals-sa
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Mar 20, 2024
Approval ID
8YzVYkJzWts
Type
生物制品
Back to NMPA Approvals